Optimizing cGVHD Management After Ruxolitinib Failure: The Role of Belumosudil in Clinical Practice (ICBMT 2026) - Oct 8, 2026 - Abstract #LS01; Pres time: Sep 17, 2026; 12:00 PM - 12:40 PM; Location: Room A(1F); "This presentation reviews evidence supporting strategic treatment sequencing after ruxolitinib failure, practical approaches to early identification of non-responders and intolerant patients, and multidisciplinary strategies for optimizing belumosudil therapy. Emphasis is placed on enhancing consistency in cGVHD management criteria across institutions to improve long-term outcomes for patients navigating this complex therapeutic landscape."
Clinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Fibrosis • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases
|